Clinical Trials
15 trialsNCT00113763 2022-11-07
Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer
Amgen
Phase 3 Completed
NCT00364013 2022-11-07
PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy
Amgen
Phase 3 Completed
NCT00446446 2022-10-05
PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
Amgen
Phase 2 Completed
NCT00339183 2022-09-23
Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone
Amgen
Phase 3 Completed
NCT01750918 2021-10-29
BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
Novartis
Phase 1/2 Completed
NCT00115765 2018-10-17
PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study
Amgen
Phase 3 Completed
NCT00418938 2018-10-17
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
Amgen
Phase 2 Completed
NCT00547157 2017-03-15
Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Amgen
Phase 2 Completed
NCT00563316 2016-04-12
Effect of Panitumumab on the Pharmacokinetics of Irinotecan
Amgen
Phase 1 Completed
NCT00411450 2016-02-15
PRECEPT
Amgen
Phase 2 Completed
NCT00879385 2014-10-31
KRAS Wild-type Metastatic Colorectal Cancer Trial
University of Utah
Phase 1 Completed
NCT00630786 2014-02-06
Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study
Amgen
Phase 1/2 Completed
NCT00113776 2011-01-21
Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal Cancer
Amgen
Phase 2 Completed
NCT00091806 2009-07-10
Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors
Amgen
Phase 1 Completed
NCT00034346 2007-12-24
ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Amgen
Phase 2 Completed